ESMO 2022 Conference Coverage
Playback speed
10 seconds
ESMO 2022 on 4.5-Year Follow-Up From KEYNOTE-240: Pembrolizumab vs. Placebo as 2L Treatment for Sorafenib-Treated aHCC
By
ESMO 2022 Conference Coverage
FEATURING
Julien Edeline
By
ESMO 2022 Conference Coverage
FEATURING
Julien Edeline
122 views
September 16, 2022
Comments 0
Login to view comments.
Click here to Login
GI